Trial · NCT05715528
Results by group39
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 39
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 29 | Obeldesivir | 5.9 | 95% Confidence Interval 5.4 to 6.1 | days | |
| Time to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 29 | Placebo | 6.0 | 95% Confidence Interval 5.8 to 6.3 | days | |
| Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Obeldesivir | 5.4 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Placebo | 5.7 | percentage of participants | ||
| Percentage of Participants Experiencing Laboratory Abnormalities | Obeldesivir | Any grade | 77.5 | percentage of participants | |
| Percentage of Participants Experiencing Laboratory Abnormalities | Placebo | Any grade | 78.5 | percentage of participants | |
| Percentage of Participants Experiencing Laboratory Abnormalities | Obeldesivir | Grade 3 or 4 | 6.1 | percentage of participants | |
| Percentage of Participants Experiencing Laboratory Abnormalities | Placebo | Grade 3 or 4 | 8.5 | percentage of participants | |
| Percentage of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation | Obeldesivir | SAEs | 0.2 | percentage of participants | |
| Percentage of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation | Placebo | SAEs | 0.4 | percentage of participants | |
| Percentage of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation | Obeldesivir | AEs leading to study drug discontinuation | 0.1 | percentage of participants | |
| Percentage of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation | Placebo | AEs leading to study drug discontinuation | 0 | percentage of participants | |
| Time to COVID-19 Symptom Resolution by Day 29 | Obeldesivir | 9.2 | 95% Confidence Interval 8.9 to 10.0 | days | |
| Time to COVID-19 Symptom Resolution by Day 29 | Placebo | 9.3 | 95% Confidence Interval 8.9 to 10.1 | days | |
| Percentage of Participants With Moderate Relapse of COVID-19 Symptoms by Day 29 | Obeldesivir | 8.3 | 95% Confidence Interval 6.4 to 10.5 | percentage of participants | |
| Percentage of Participants With Moderate Relapse of COVID-19 Symptoms by Day 29 | Placebo | 9.0 | 95% Confidence Interval 7.1 to 11.3 | percentage of participants | |
| Percentage of Participants With COVID-19 Related Medically Attended Visits (MAVs) or All-cause Death by Day 29 | Obeldesivir | 0.1 | 95% Confidence Interval 0.0 to 0.3 | percentage of participants | |
| Percentage of Participants With COVID-19 Related Medically Attended Visits (MAVs) or All-cause Death by Day 29 | Placebo | 0.2 | 95% Confidence Interval 0.0 to 0.5 | percentage of participants | |
| Percentage of Participants With COVID-19 Related Hospitalization or All-cause Death by Day 29 | Obeldesivir | 0 | percentage of participants | ||
| Percentage of Participants With COVID-19 Related Hospitalization or All-cause Death by Day 29 | Placebo | 0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05715528/results